Cargando…

Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice

PURPOSE: TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concent...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoneyama, Tomoki, Sato, Sho, Sykes, Andy, Fradley, Rosa, Stafford, Stuart, Bechar, Shyam, Howley, Eimear, Patel, Toshal, Tagawa, Yoshihiko, Moriwaki, Toshiya, Asahi, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478952/
https://www.ncbi.nlm.nih.gov/pubmed/32901384
http://dx.doi.org/10.1007/s11095-020-02893-x
_version_ 1783580165022941184
author Yoneyama, Tomoki
Sato, Sho
Sykes, Andy
Fradley, Rosa
Stafford, Stuart
Bechar, Shyam
Howley, Eimear
Patel, Toshal
Tagawa, Yoshihiko
Moriwaki, Toshiya
Asahi, Satoru
author_facet Yoneyama, Tomoki
Sato, Sho
Sykes, Andy
Fradley, Rosa
Stafford, Stuart
Bechar, Shyam
Howley, Eimear
Patel, Toshal
Tagawa, Yoshihiko
Moriwaki, Toshiya
Asahi, Satoru
author_sort Yoneyama, Tomoki
collection PubMed
description PURPOSE: TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concentrations as a pharmacodynamic (PD) readout was established in mice. METHODS: PK, TO and PD time-profiles were obtained in mice and analyzed by mechanistic binding kinetics model connected with an indirect response model in a step wise fashion. Brain distribution was investigated to elucidate a possible mechanism driving the hysteresis between PK and TO. RESULTS: The observed nonlinear PK/TO/PD relationship was well captured by mechanistic modeling framework within a wide dose range of TAK-831 in mice. Remarkably different brain distribution was observed between target and reference regions, suggesting that the target-mediated slow binding kinetics rather than slow penetration through the blood brain barrier caused the observed distinct kinetics between PK and TO. CONCLUSION: A quantitative mechanistic model for concentration- and time-dependent nonlinear PK/TO/PD relationship was established for TAK-831 in mice with accounting for possible rate-determining process. The established mechanistic modeling framework will provide a quantitative means for multilayer biomarker-assisted clinical development in multiple central nervous system indications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-020-02893-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7478952
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-74789522020-09-28 Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice Yoneyama, Tomoki Sato, Sho Sykes, Andy Fradley, Rosa Stafford, Stuart Bechar, Shyam Howley, Eimear Patel, Toshal Tagawa, Yoshihiko Moriwaki, Toshiya Asahi, Satoru Pharm Res Research Paper PURPOSE: TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concentrations as a pharmacodynamic (PD) readout was established in mice. METHODS: PK, TO and PD time-profiles were obtained in mice and analyzed by mechanistic binding kinetics model connected with an indirect response model in a step wise fashion. Brain distribution was investigated to elucidate a possible mechanism driving the hysteresis between PK and TO. RESULTS: The observed nonlinear PK/TO/PD relationship was well captured by mechanistic modeling framework within a wide dose range of TAK-831 in mice. Remarkably different brain distribution was observed between target and reference regions, suggesting that the target-mediated slow binding kinetics rather than slow penetration through the blood brain barrier caused the observed distinct kinetics between PK and TO. CONCLUSION: A quantitative mechanistic model for concentration- and time-dependent nonlinear PK/TO/PD relationship was established for TAK-831 in mice with accounting for possible rate-determining process. The established mechanistic modeling framework will provide a quantitative means for multilayer biomarker-assisted clinical development in multiple central nervous system indications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-020-02893-x) contains supplementary material, which is available to authorized users. Springer US 2020-08-05 2020 /pmc/articles/PMC7478952/ /pubmed/32901384 http://dx.doi.org/10.1007/s11095-020-02893-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Paper
Yoneyama, Tomoki
Sato, Sho
Sykes, Andy
Fradley, Rosa
Stafford, Stuart
Bechar, Shyam
Howley, Eimear
Patel, Toshal
Tagawa, Yoshihiko
Moriwaki, Toshiya
Asahi, Satoru
Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
title Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
title_full Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
title_fullStr Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
title_full_unstemmed Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
title_short Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice
title_sort mechanistic multilayer quantitative model for nonlinear pharmacokinetics, target occupancy and pharmacodynamics (pk/to/pd) relationship of d-amino acid oxidase inhibitor, tak-831 in mice
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478952/
https://www.ncbi.nlm.nih.gov/pubmed/32901384
http://dx.doi.org/10.1007/s11095-020-02893-x
work_keys_str_mv AT yoneyamatomoki mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT satosho mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT sykesandy mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT fradleyrosa mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT staffordstuart mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT becharshyam mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT howleyeimear mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT pateltoshal mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT tagawayoshihiko mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT moriwakitoshiya mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice
AT asahisatoru mechanisticmultilayerquantitativemodelfornonlinearpharmacokineticstargetoccupancyandpharmacodynamicspktopdrelationshipofdaminoacidoxidaseinhibitortak831inmice